Biology:p38 mitogen-activated protein kinases

From HandWiki
Short description: Protein family

Main page: Biology:Mitogen-activated protein kinase
mitogen-activated protein kinase 11
Identifiers
SymbolMAPK11
Alt. symbolsPRKM11
NCBI gene5600
HGNC6873
OMIM602898
RefSeqNM_002751
UniProtQ15759
Other data
EC number2.7.11.24
LocusChr. 22 q13.33
mitogen-activated protein kinase 12
Identifiers
SymbolMAPK12
Alt. symbolsSAPK3
NCBI gene6300
HGNC6874
OMIM602399
RefSeqNM_002969
UniProtP53778
Other data
EC number2.7.11.24
LocusChr. 22 q13.3
mitogen-activated protein kinase 13
Identifiers
SymbolMAPK13
Alt. symbolsPRKM13
NCBI gene5603
HGNC6875
OMIM602899
RefSeqNM_002754
UniProtO15264
Other data
EC number2.7.11.24
LocusChr. 6 p21
mitogen-activated protein kinase 14
Identifiers
SymbolMAPK14
Alt. symbolsCSPB1, CSBP1, CSBP2
NCBI gene1432
HGNC6876
OMIM600289
RefSeqNM_001315
UniProtQ16539
Other data
EC number2.7.11.24
LocusChr. 6 p21.3-21.2

p38 mitogen-activated protein kinases are a class of mitogen-activated protein kinases (MAPKs) that are responsive to stress stimuli, such as cytokines, ultraviolet irradiation, heat shock, and osmotic shock, and are involved in cell differentiation, apoptosis and autophagy. Persistent activation of the p38 MAPK pathway in muscle satellite cells (muscle stem cells) due to ageing, impairs muscle regeneration.[1][2]

p38 MAP Kinase (MAPK), also called RK or CSBP (Cytokinin Specific Binding Protein), is the mammalian orthologue of the yeast Hog1p MAP kinase,[3] which participates in a signaling cascade controlling cellular responses to cytokines and stress.

Four p38 MAP kinases, p38-α (MAPK14), -β (MAPK11), -γ (MAPK12 / ERK6), and -δ (MAPK13 / SAPK4), have been identified. Similar to the SAPK/JNK pathway, p38 MAP kinase is activated by a variety of cellular stresses including osmotic shock, inflammatory cytokines, lipopolysaccharides (LPS), ultraviolet light, and growth factors.

MKK3 and SEK activate p38 MAP kinase by phosphorylation at Thr-180 and Tyr-182. Activated p38 MAP kinase has been shown to phosphorylate and activate MAPKAP kinase 2 and to phosphorylate the transcription factors ATF2, Mac, MEF2, and p53.[4] p38 also has been shown to phosphorylate post-transcriptional regulating factors like TTP,[5] and in fruit flies it plays a role in regulating the circadian clock.[6]

Clinical significance

Oxidative stress is the most powerfully specific stress activating p38 MAPK.[7] Abnormal activity (higher or lower than physiological) of p38 has been implicated in pathological stresses in several tissues, that include neuronal,[8][9][10] bone,[11] lung,[12] cardiac and skeletal muscle,[13][14] red blood cells,[15] and fetal tissues.[16] The protein product of proto-oncogene RAS can increase activity of p38, and thereby cause excessively high activity of transcription factor NF-κB. This transcription factor is normally regulated from intracellular pathways that integrate signals from the surrounding tissue and the immune system. In turn these signals coordinate between cell survival and cell death. Dysregulated NF-κB activity can activate genes that cause cancer cell survival, and can also activate genes that facilitate cancer cell metastasis to other tissues.[17] P38 was also shown to correlate with outcome of glioblastoma - higher pathway activity is associated with low survival.[18]

Inhibitors

p38 inhibitors are being sought for possible therapeutic effect on autoimmune diseases and inflammatory processes,[19] e.g. pamapimod.[20] Some have started clinical trials, e.g. PH-797804 for COPD.[21] Other p38 inhibitors include BIRB 796, VX-702, SB239063, SB202190, SB203580, SCIO 469, and BMS 582949.

As of 2020, losmapimod, a p38 inhibitor, is being investigated for the treatment of facioscapulohumeral muscular dystrophy (FSHD) on the basis of p38 inhibition inhibiting the effects of DUX4.[22]

References

  1. ↑ "Rejuvenation of the muscle stem cell population restores strength to injured aged muscles". Nature Medicine 20 (3): 255–64. 2014. doi:10.1038/nm.3464. PMID 24531378. 
  2. ↑ "Regulation of Muscle Stem Cell Functions: A Focus on the p38 MAPK Signaling Pathway". Frontiers in Cell and Developmental Biology 4: 91. 2016. doi:10.3389/fcell.2016.00091. PMID 27626031. 
  3. ↑ "A MAP kinase targeted by endotoxin and hyperosmolarity in mammalian cells". Science 265 (5173): 808–11. August 1994. doi:10.1126/science.7914033. PMID 7914033. Bibcode: 1994Sci...265..808H. 
  4. ↑ "ERKs and p38 kinase phosphorylate p53 protein at serine 15 in response to UV radiation". Journal of Biological Chemistry 275 (27): 20444–20449. July 2000. doi:10.1074/jbc.M001020200. PMID 10781582. 
  5. ↑ "The p38 MAPK pathway inhibits tristetraprolin-directed decay of interleukin-10 and pro-inflammatory mediator mRNAs in murine macrophages". FEBS Letters 583 (12): 1933–8. June 2009. doi:10.1016/j.febslet.2009.04.039. PMID 19416727. 
  6. ↑ "The MAP Kinase p38 Is Part of Drosophila melanogaster's Circadian Clock". PLOS Genetics 10 (8): e1004565. 2014. doi:10.1371/journal.pgen.1004565. PMID 25144774. 
  7. ↑ "Regulation of senescence traits by MAPKs". GeroScience 42 (2): 397–408. 2020. doi:10.1007/s11357-020-00183-3. PMID 32300964. 
  8. ↑ "RAGE and Alzheimer's disease: a progression factor for amyloid-beta-induced cellular perturbation?". Journal of Alzheimer's Disease 16 (4): 833–43. 2009. doi:10.3233/JAD-2009-1030. PMID 19387116. 
  9. ↑ "Microglial p38α MAPK is a key regulator of proinflammatory cytokine up-regulation induced by toll-like receptor (TLR) ligands or beta-amyloid (Aβ)". Journal of Neuroinflammation 8: 79. July 2011. doi:10.1186/1742-2094-8-79. PMID 21733175. 
  10. ↑ "Retention of normal glia function by an isoform-selective protein kinase inhibitor drug candidate that modulates cytokine production and cognitive outcomes". Journal of Neuroinflammation 14 (1): 75. April 2017. doi:10.1186/s12974-017-0845-2. PMID 28381303. 
  11. ↑ "Mechanisms modulating inflammatory osteolysis: a review with insights into therapeutic targets". Pathology, Research and Practice 204 (10): 695–706. 2008. doi:10.1016/j.prp.2008.07.002. PMID 18757139. 
  12. ↑ "Kinases as Novel Therapeutic Targets in Asthma and Chronic Obstructive Pulmonary Disease". Pharmacological Reviews 68 (3): 788–815. July 2016. doi:10.1124/pr.116.012518. PMID 27363440. 
  13. ↑ "The Role of p38 MAPK in the Development of Diabetic Cardiomyopathy". International Journal of Molecular Sciences 17 (7): E1037. June 2016. doi:10.3390/ijms17071037. PMID 27376265. 
  14. ↑ "Regulation of Muscle Stem Cell Functions: A Focus on the p38 MAPK Signaling Pathway". Frontiers in Cell and Developmental Biology 4: 91. August 2016. doi:10.3389/fcell.2016.00091. PMID 27626031. 
  15. ↑ "Suicidal death of erythrocytes in cancer and its chemotherapy: A potential target in the treatment of tumor-associated anemia". International Journal of Cancer 141 (8): 1522–1528. October 2017. doi:10.1002/ijc.30800. PMID 28542880. 
  16. ↑ "Mapping out p38MAPK". American Journal of Reproductive Immunology 77 (5): e12652. May 2017. doi:10.1111/aji.12652. PMID 28194826. 
  17. ↑ "Aberrant control of NF-κB in cancer permits transcriptional and phenotypic plasticity, to curtail dependence on host tissue: molecular mode". Cancer Biology & Medicine 14 (3): 254–270. August 2017. doi:10.20892/j.issn.2095-3941.2017.0029. PMID 28884042. 
  18. ↑ Ben-Hamo, Rotem; Efroni, Sol (2013-04-11). "hsa-miR-9 and drug control over the P38 network as driving disease outcome in GBM patients" (in en). Systems Biomedicine 1 (2): 76–83. doi:10.4161/sysb.25815. ISSN 2162-8130. 
  19. ↑ "Pathway to the clinic: inhibition of P38 MAP kinase. A review of ten chemotypes selected for development". Current Topics in Medicinal Chemistry 5 (10): 1017–29. 2005. doi:10.2174/1568026054985939. PMID 16178744. 
  20. ↑ "Pamapimod, a novel p38 mitogen-activated protein kinase inhibitor: preclinical analysis of efficacy and selectivity". The Journal of Pharmacology and Experimental Therapeutics 327 (3): 610–9. December 2008. doi:10.1124/jpet.108.139006. PMID 18776065. 
  21. ↑ "Novel p38 Inhibitor Shows Promise as Anti-Inflammatory Treatment for Patients With COPD". 2010. http://www.docguide.com/novel-p38-inhibitor-shows-promise-anti-inflammatory-treatment-patients-copd. 
  22. ↑ Mellion, M.; Ronco, L.; Thompson, D.; Hage, M.; Brooks, S.; van Brummelen, E.; Pagan, L.; Badrising, U. et al. (October 2019). "O.25Phase 1 clinical trial of losmapimod in FSHD: safety, tolerability and target engagement". Neuromuscular Disorders 29: S123. doi:10.1016/j.nmd.2019.06.308. 

External links




Retrieved from "https://handwiki.org/wiki/index.php?title=Biology:P38_mitogen-activated_protein_kinases&oldid=3552410"